The online version of this article (https://doi.org/10.1007/s12325-019-01085-3) contains supplementary material, which is available to authorized users.
To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.9736163.
Diroximel fumarate (DRF) is a novel oral fumarate in development for patients with relapsing forms of multiple sclerosis (MS). Clinical findings from the DRF development program suggest that rates of gastrointestinal (GI) treatment-emergent adverse events (TEAEs) and discontinuation due to GI TEAEs are low, based on clinical and real-world observations of other fumaric acid esters, including dimethyl fumarate (DMF). The incidence of GI TEAEs varies from 40 to 88% in clinical and real-world studies of DMF. The objective of this study is to present GI tolerability findings from the EVOLVE-MS-1 study and present biologic hypotheses for the improved GI properties of DRF.
GI TEAEs and treatment discontinuation because of GI TEAEs were assessed in DRF-treated patients with relapsing-remitting MS who were participating in the ongoing, 96-week, open-label, phase 3 EVOLVE-MS-1 study.
As of March 30, 2018, a total of 696 patients were enrolled in EVOLVE-MS-1. GI TEAEs were reported in 30.9% (215/696) of patients; the vast majority (96%; 207/215) experienced events that were mild or moderate in severity. When GI AEs did occur, they occurred early in treatment, resolved (88.8%; 191/215), and were of short duration [median 7.5 (range 1–87) days] in most patients. GI TEAEs led to < 1% of patients discontinuing treatment.
We suggest that the distinct chemical structure of DRF contributes to the observed low rates of GI TEAEs and GI-associated treatment discontinuations, possibly due to a combination of several factors. We hypothesize that these factors may include less reactivity with off-target proteins and/or lower production of a methanol leaving group that may contribute to GI irritation. A direct comparison of GI tolerability with DRF versus DMF is being evaluated in the EVOLVE-MS-2 study.
ClinicalTrials.gov number NCT02634307.
Alkermes Inc. (Waltham, MA, USA) and Biogen (Cambridge, MA, USA).
Supplementary material 1 (DOCX 15 kb)12325_2019_1085_MOESM1_ESM.docx
Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–107. CrossRef
Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–97. CrossRef
Gold R, Arnold DL, Bar-Or A, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Mult Scler. 2017;23(2):253–65. CrossRef
Cohan SL, Moses H, Calkwood J, et al. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY). Mult Scler Relat Disord. 2018;22:27–34. CrossRef
Kresa-Reahl K, Repovic P, Robertson D, Okwuokenye M, Meltzer L, Mendoza JP. Effectiveness of delayed-release dimethyl fumarate on clinical and patient-reported outcomes in patients with relapsing multiple sclerosis switching from glatiramer acetate: RESPOND, a prospective observational study. Clin Ther. 2018;40(12):2077–87. CrossRef
Parodi B, Rossi S, Morando S, et al. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol. 2015;130(2):279–95. CrossRef
Chen H, Assmann JC, Krenz A, et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. J Clin Investig. 2014;124(5):2188–92. CrossRef
Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134(Pt 3):678–92. CrossRef
European Medicines Agency. TECFIDERA summary of product characteristics. https://ec.europa.eu/health/documents/community-register/2018/20180528141209/anx_141209_en.pdf. Accessed 19 Feb 2019.
Fox EJ, Vasquez A, Grainger W, et al. Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE). Int J MS Care. 2016;18(1):9–18. CrossRef
Mrowietz U, Morrison PJ, Suhrkamp I, Kumanova M, Clement B. The pharmacokinetics of fumaric acid esters reveal their in vivo effects. Trends Pharmacol Sci. 2018;39(1):1–12. CrossRef
Vollmer B, Ontaneda D, Bandyopadhyay A, et al. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurol Clin Pract. 2018;8(4):292–301. CrossRef
Mirabella M, Prosperini L, Lucchini M, et al. Safety and efficacy of dimethyl fumarate in multiple sclerosis: an Italian, multicenter, real-world study. CNS Drugs. 2018;32(10):963–70. CrossRef
Centers for Disease Control and Prevention. Methanol: systemic agent U.S. Department of Health and Human Services. https://www.cdc.gov/niosh/ershdb/emergencyresponsecard_29750029.html. Accessed 23 Apr 2019.
Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302. CrossRef
de Haan P, von Blomberg-van der Flier BM, de Groot J, Nieboer C, Bruynzeel DP. The risk of sensibilization and contact urticaria upon topical application of fumaric acid derivatives. Dermatology. 1994;188(2):126–30. CrossRef
Lammintausta K, Zimerson E, Winhoven S, et al. Sensitization to dimethyl fumarate with multiple concurrent patch test reactions. Contact Dermat. 2010;62(2):88–96. CrossRef
Moon CS. Estimations of the lethal and exposure doses for representative methanol symptoms in humans. Ann Occup Environ Med. 2017;29:44. CrossRef
Liesivuori J, Savolainen H. Methanol and formic acid toxicity: biochemical mechanisms. Pharmacol Toxicol. 1991;69(3):157–63. CrossRef
Kraut JA, Mullins ME. Toxic alcohols. N Engl J Med. 2018;378(3):270–80. CrossRef
The Human Protein Atlas. Alcohol dehydrogenases. https://www.proteinatlas.org/search/alcohol+dehydrogenase. Accessed 23 Apr 2019.
United States Food and Drug Administration. Additional information about high-intensity sweetners permitted for use in food in the United States U.S. Department of Health and Human Services. https://www.fda.gov/food/ingredientspackaginglabeling/foodadditivesingredients/ucm397725.htm. Accessed 23 Apr 2019.
Tsang WS, Clarke MA, Parrish FW. Determination of aspartame and its breakdown products in soft drinks by reverse-phase chromatography with UV detection. J Agric Food Chem. 1985;33(4):734–8. CrossRef
Haupt VJ, Daminelli S, Schroeder M. Drug promiscuity in PDB: protein binding site similarity is key. PLoS One. 2013;8(6):e65894. CrossRef
von Glehn F, Dias-Carneiro RPC, Moraes AS, et al. Dimethyl fumarate downregulates the immune response through the HCA 2/GPR109A pathway: implications for the treatment of multiple sclerosis. Mult Scler Relat Disord. 2018;23:46–50. CrossRef
Hosseini A, Masjedi A, Baradaran B, et al. Dimethyl fumarate: regulatory effects on the immune system in the treatment of multiple sclerosis. J Cell Physiol. 2019;234(7):9943–55. CrossRef
Makins R, Ballinger A. Gastrointestinal side effects of drugs. Expert Opin Drug Saf. 2003;2(4):421–9. CrossRef
Leong RW, Chan FK. Drug-induced side effects affecting the gastrointestinal tract. Expert Opin Drug Saf. 2006;5(4):585–92. CrossRef
Schmidt TJ, Ak M, Mrowietz U. Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl- l-cysteine—preparation of S-substituted thiosuccinic acid esters. Bioorg Med Chem. 2007;15(1):333–42. CrossRef
- Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study
Michael J. Palte
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II